Hurley Medical Center, Michigan State University, Flint, MI, USA.
General Practice NHS West Essex, UK.
Clin Exp Hypertens. 2020;42(2):177-180. doi: 10.1080/10641963.2019.1601204. Epub 2019 Apr 2.
: Previous studies have already shown a link between vitamin D deficiency and hypertension. The impact of vitamin D deficiency in resistant hypertension is currently unknown. This study examined whether an association between the two entities exists.: We analysed 2953 known hypertensive subjects surveyed by NHANES (National Health and Nutrition Examination Survey) among the United States population between 2003 and 2006. Subjects were categorized as having either resistant hypertension or hypertension based on the number of anti-hypertensives in use and their overall blood pressure control. Subjects were also categorized as vitamin D deficient if they had 25(OH)D (25-hydroxycholecalciferol) levels less than 20ng/ml.: Out of the 2953 subjects, 362 (12%) were found to have resistant hypertension and 2591 (88%) had controlled hypertension. The prevalence of vitamin D deficiency in resistant hypertension and controlled hypertension groups was 61% and 46% respectively. Following adjustments for other variables such as age, renal function, obesity and ethnicity, the odds ratio (OR) for concomitant presence of resistant hypertension and vitamin D deficiency was 3.49 (95% confidence interval [CI] 1.69-7.17; < 0.009). The OR for having resistant hypertension and chronic kidney disease, older age and obesity were 2.5 (95% CI 1.5-4; < 0.0003), 1.034 (95% CI 1.02-1.07; < 0.0001) and 1.048 (95% CI 1.02-1.07; < 0.0001) respectively.: This study found a statistically significant association between vitamin D deficiency and resistant hypertension. US, United States; NHANES, National Health and Nutrition Examination Survey; UVB, ultraviolet B; PTH, parathyroid hormone; IRB, Institutional Review Board; NCHS, National Centers for Health Statistics; BMI, body mass index; BP, blood pressure; ACE, angiotensin-converting-enzyme; RIA, Radio Immuno Assay; SAS, Statistical Analysis System; 25(OH)D or 25OHD3, 25-hydroxycholecalciferol or 25-hydroxyvitamin D3 or calcifediol or calcidiol; Vitamin D3, cholecalciferol; OR, odds ratio; CI, confidence interval.
: 先前的研究已经表明维生素 D 缺乏与高血压之间存在关联。目前尚不清楚维生素 D 缺乏症在耐药性高血压中的影响。本研究旨在检验这两者之间是否存在关联。: 我们分析了 2003 年至 2006 年期间美国国家健康和营养检查调查（NHANES）中 2953 名已知高血压患者的数据。根据使用的抗高血压药物数量及其总体血压控制情况，将患者分为耐药性高血压或高血压。如果 25（OH）D（25-羟胆钙化醇）水平低于 20ng/ml，患者也被归类为维生素 D 缺乏症。: 在 2953 名患者中，发现 362 名（12%）患有耐药性高血压，2591 名（88%）患有高血压。耐药性高血压组和高血压组维生素 D 缺乏症的患病率分别为 61%和 46%。在调整了年龄、肾功能、肥胖和种族等其他变量后，同时存在耐药性高血压和维生素 D 缺乏症的比值比（OR）为 3.49（95%置信区间 [CI] 1.69-7.17；<0.009）。同时患有耐药性高血压和慢性肾病、年龄较大和肥胖的 OR 分别为 2.5（95% CI 1.5-4；<0.0003）、1.034（95% CI 1.02-1.07；<0.0001）和 1.048（95% CI 1.02-1.07；<0.0001）。: 本研究发现维生素 D 缺乏症与耐药性高血压之间存在统计学显著关联。US，美国；NHANES，国家健康和营养检查调查；UVB，紫外线 B；PTH，甲状旁腺激素；IRB，机构审查委员会；NCHS，国家卫生统计中心；BMI，体重指数；BP，血压；ACE，血管紧张素转换酶；RIA，放射免疫测定；SAS，统计分析系统；25（OH）D 或 25OHD3，25-羟胆钙化醇或 25-羟基维生素 D3 或 calcifediol 或 calcidiol；维生素 D3，胆钙化醇；OR，比值比；CI，置信区间。
